Dongbang FTL Co., Ltd. is a specialized research, development, and manufacturing company for Active Pharmaceutical Ingredients (API), established in 1990. Based on its proprietary synthetic process technology and cGMP-certified production facilities, it supplies key raw materials for various specialized medicines, including anticoagulants, diabetes treatments, and hypertension treatments, to leading pharmaceutical companies both domestically and internationally. In particular, it is expanding exports to developed markets such as Japan and Europe, growing into a global API specialist.

"Dongbang FTL develops the best medicines through research for a healthy life, striving to make human lives healthier and happier with the highest quality pharmaceuticals. Since its establishment in 1990, it has been dedicated to the specialized research, development, and manufacturing of Active Pharmaceutical Ingredients (API). Based on proprietary synthetic process technology and cGMP-certified production facilities, it has established a strong market presence by supplying high-purity, high-quality raw materials at competitive prices."

Business Areas

• Research, Development, and Production of Synthetic Active Pharmaceutical Ingredients: Our core business is the research, development, and commercial production of generic Active Pharmaceutical Ingredients (API). We independently develop optimal synthetic processes for key substances of off-patent original drugs, considering economic efficiency and environmental friendliness, and stably supply them in large quantities from cGMP-certified facilities to domestic and international finished drug manufacturers.
• Development of Natural Product Active Pharmaceutical Ingredients and Products: We were the first in Korea to obtain GMP certification for herbal active pharmaceutical ingredients and are continuously investing in the research and development of new herbal substances and new drugs. We are developing various natural product-based medicines, including an injectable hair loss treatment using human hair keratin and a Phase 2 clinical trial for a benign prostatic hyperplasia treatment.
• CDMO and New Drug Development: We are collaborating with leading domestic and international pharmaceutical and bio companies and research institutions, undertaking over 35 CMC (Chemistry, Manufacturing and Controls) and CDMO (Contract Development and Manufacturing Organization) projects. We are also investing in our own new drug development using PROTAC technology, securing future growth engines.

Products

• Anti-inflammatory Analgesic Active Pharmaceutical Ingredients: We hold a high market share in the Japanese anti-inflammatory analgesic raw material market, producing and supplying various anti-inflammatory analgesic raw materials such as Celecoxib, Felbinac, Ketoprofen, Loxoprofen, Mefenamic Acid, and Meloxicam.
• Diabetes and Prostate Treatment Active Pharmaceutical Ingredients: We are expanding our business into high-value-added products, producing and supplying active pharmaceutical ingredients for diabetes treatments (e.g., Mitiglinide) and prostate treatments (e.g., Silodosin, Tamsulosin).
• COVID-19 Treatment Active Pharmaceutical Ingredients: Selected by the Medicines Patent Pool (MPP) as a manufacturer of active pharmaceutical ingredients for MSD's oral COVID-19 treatment Molnupiravir (Lagevrio) and Pfizer's Paxlovid, we are contributing to the improvement of human health.

Special Notes

• Advanced Synthesis Technology and Strict Quality Control: Based on over 30 years of accumulated advanced synthetic process technology, we produce high-purity, high-quality active pharmaceutical ingredients. We meet world-class quality standards, including Japan's PMDA, and have demonstrated excellent quality control capabilities, receiving no observations in recent KFDA GMP audits.
• Global Market Competitiveness and Export-Oriented Company: Having obtained GMP certification in numerous countries, including Korea's MFDS, Japan's PMDA, Australia's TGA, and France's ANSM, we are recognized for our technology and excellent pharmaceutical manufacturing capabilities in the global market. As an export-oriented company with overseas exports accounting for over 60% of sales, we are expanding our business into developed markets such as Japan and Europe.
• Continuous R&D Investment and New Drug Development Capabilities: We are dedicated to the development of active pharmaceutical ingredients and are expanding new pipelines through continuous R&D investment. Through the establishment of subsidiaries and joint ventures, we are also challenging ourselves in the development of innovative new drugs, such as natural product-based materials and small molecule-based anticancer drugs, thereby strengthening our future growth engines.

Recruitment Information

• Main Hiring Positions: Synthetic Research Scientist, Public Affairs Team, Finance Team, Planning Team, CEO Secretary, Cost Accounting/Taxation Specialist, Production Management Team, Overseas Sales Team, General Affairs Team, Managing Pharmacist, Synthetic API Production Worker, etc.
• Benefits: Health check-ups, support for various family events, retirement pension, dormitory operation, commuter bus service, in-house cafeteria provided

💡 A Word from JobPloy
Dongbang FTL Co., Ltd. is a company specializing in the research, development, and production of active pharmaceutical ingredients, where precise chemical processes and strict quality control are extremely important. Therefore, foreign workers are required to demonstrate high concentration and accuracy in their assigned duties and must pay particular attention to adhering to safety regulations and understanding quality standards. There will be many opportunities to grow with the company through continuous learning and teamwork.